Menu Search
Equities

Nipro Corp

5FA:FRA

Nipro Corp

Actions
  • Price (EUR)6.90
  • Today's Change-0.10 / -1.43%
  • Shares traded-1.00
  • 1 Year change+2.99%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 16:15 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NIPRO CORPORATION is a manufacturer of medical devices, pharmaceuticals and instrument products. The Company has three segments. The Medical-Related segment involves in the sale of injections and infusions, artificial organs, high function and dialysis related medical equipment, and diabetes, generics and kits related medicine products in Japan, as well as the sales of medical devices for injection and infusion, artificial organs and diabetes in overseas markets. The Pharmaceutical-Related segment involves in the manufacture and sale of pharmaceuticals. The Pharma Packaging segment sells glass for vials and ampoules as medical glass in Japan, thermos glass for lighting and glass for lighting equipment.

  • Revenue in JPY (TTM)586.79bn
  • Net income in JPY11.11bn
  • Incorporated1948
  • Employees38.77k
  • Location
    Nipro Corp3-26, Senrioka shin-machiSETTSU-SHI 566-8510JapanJPN
  • Phone+81 663722331
  • Fax+81 663717422
  • Websitehttps://www.nipro.co.jp/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.